RECaST-Surv is proposed, a Bayesian transfer-learning framework for time-to-event outcomes that extends the RECaST method to survival settings and maintains near-nominal Type I error across challenging settings while improving power by roughly 10%--12% over standard analyses.
Abstract
Randomized trials with limited concurrent control information---including but not limited to unequal-randomization settings---can offer ethical and practical advantages, especially in pediatric and rare diseases, but they often lose power because fewer control patients are available for direct comparison. Borrowing information from external controls may improve efficiency, but can also inflate the Type I error rate when the external and trial populations are not sufficiently comparable. We propose RECaST-Surv, a Bayesian transfer-learning framework for time-to-event outcomes that extends the RECaST method to survival settings. The method learns a structural survival model from external control data and calibrates it to the concurrent control arm of the current trial through a Cauchy random effect. To improve frequentist operating characteristics, we further develop a bootstrap-based procedure to calibrate the testing rule for Type I error control. RECaST-Surv can accommodate multiple external datasets and requires only summary-level information from external sources. Simulation studies show that the method maintains near-nominal Type I error across challenging settings while improving power by roughly 10%--12% over standard analyses. In an Amyotrophic Lateral Sclerosis trial emulation, RECaST-Surv increased power from 82.8% to 95.7% relative to the no-borrowing RCT analysis, while maintaining acceptable error control.
When resources are limited in a randomized trial, a common strategy is to augment data from the control arm with external controls. We propose a hybrid group sequential Bayesian design that uses this approach to compare time-to-event distributions. The design allows between-treatment effects to differ between patient s...
Xin-Yi He, Peter F. Thall, Ying Yuan et al.· 0 citations
Clinical trials using a hybrid control, which integrates a randomized control with external control data, may be one solution to facilitate clinical development where traditional randomized controlled trials are challenging. Despite its attractive features, systematic differences between controls can introduce bias in...
Ryo Sawamoto, Koji Oba, Y. Matsuyama· Biometrical journal. Biometr...· 0 citations
This work proposes a novel data-driven, adaptive procedure that identifies the optimal restriction time from a continuous range by maximizing a criterion balancing effect size and estimation precision, and provides a rigorous theoretical foundation that accounts for the additional variability introduced by adaptive sel...
Jing-Hao Sun, D. Schaubel, E. T. Tchetgen Tchetgen· Biometrika· 0 citations
Results of a clinical trial may misrepresent the target population. Inappropriate inclusion/exclusion criteria, selective recruitment, and differential participation may restrict the number of patients who consent to join the study. Frequently, they differ from the real-world population in terms of key outcome-related...
J. Efird, Genevieve N. Dupuis, Yuk-Ming Choi et al.· International Journal of Env...· 0 citations
Introduction: Cost-effectiveness modeling often requires the extrapolation of survival data from clinical trials. The choice of extrapolation method is often uncertain and can have a profound effect on the results. We propose an approach that incorporates external evidence (eg, from published studies, registries, or el...
David McConnell, Arthur White, F. Lamrock et al.· Medical decision making· 0 citations
Doubly robust survival estimators require nuisance models that the available information can support. We examine design and estimator dependence in TCGA breast cancer data. Treatment indicators disagree for 337 of 1076 patients; 67.4% have unobserved five-year binary outcomes; and receptor imputation expands the triple...
W. Fahmy, E. Krikun, A. Al Khateeb· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.